Research programme: polyglutamine repeat disease therapies - Cogent Neuroscience/Elan

Drug Profile

Research programme: polyglutamine repeat disease therapies - Cogent Neuroscience/Elan

Alternative Names: Polyglutamine repeat disease therapies - Cogent Neuroscience/Elan

Latest Information Update: 17 Jun 2003

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cogent Neuroscience [CEASED]
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Huntington's disease

Most Recent Events

  • 06 Dec 2002 Discontinued - Preclinical for Huntington's disease in USA (unspecified route)
  • 16 Mar 2001 Preclinical development for Huntington's disease in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top